

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

CLINICAL BENEFIT	<input checked="" type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	9/1/2024

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

IB-STIM[®] percutaneous electrical nerve field stimulator system may be considered **medically necessary** when all the following criteria are met:

- The individual is 11-18 years of age; and
- The individual has been diagnosed with functional abdominal pain associated with irritable bowel syndrome; and
- Use of the system will not exceed 4 weeks

Percutaneous electrical nerve field stimulation is considered **investigational** in all other situations as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Cranial electrotherapy stimulation (also known as cranial electrostimulation therapy or CES) is **investigational** as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Electrical stimulation of auricular acupuncture points is **investigational** as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

External trigeminal nerve stimulation to treat ADHD is considered **investigational** as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

Cross-references:

MP 6.020 Transcutaneous Electrical Nerve Stimulation

MP 6.050 Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

III. DESCRIPTION/BACKGROUND

[TOP](#)

Percutaneous Electrical Nerve Field Stimulation (PENFS)

PENFS has been proposed as a treatment of functional abdominal pain secondary to inflammatory bowel disease in children and adolescents. Irritable bowel syndrome (IBS) is estimated to affect 5% to 10% of the population globally, and accounts for between 2.4 and 3.5 million physician visits in the United States each year. Up to two-thirds of patients with IBS are female, and it is most common in patients less than 50 years of age. The cause of IBS remains unknown but is believed to be due to a dysfunction in gut-brain interaction. Symptoms of IBS can include diarrhea, constipation, or both. Abdominal pain and bloating are also common IBS symptoms. These symptoms decrease patient quality of life and create a significant healthcare burden. The American College of Gastroenterology (ACG) recommends that patients diagnosed with IBS are categorized by subtypes: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), IBS with mixed symptoms (IBS-M), or IBS without abnormal stools (IBS-U).

First-line treatment of patients with IBS generally involves dietary changes. If dietary changes fail to achieve therapeutic goals, there are numerous pharmacotherapeutic options for patients with IBS. Pharmacologic treatment is based on the IBS subtype, and the predominance of either constipation or diarrhea (Table 1).^{4,3,5} Notably, many IBS treatments are not Food and Drug Administration (FDA)-approved for children or adolescents. The American College of Gastroenterology recommends that gut-directed psychotherapy such as cognitive-behavior therapy and gut-directed hypnotherapy may be beneficial for global IBS symptoms.

Because there are few pharmacologic treatments for children and adolescents with IBS, nonpharmacologic options are commonly explored. Percutaneous electrical nerve field stimulation (PENFS) is a potential treatment option for these patients. PENFS involves a non-implantable device which stimulates nerves remotely from the site of pain and has been studied

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

for a variety of musculoskeletal or neuropathic pain conditions or for patients with opioid withdrawal. The IB-Stim device is a type of PENFS that is intended for use only in patients with IBS. The device is disposable and battery-operated. Key components of the device include a percutaneous electrical nerve field stimulator placed behind the ear which connects to a multi-wire electrode array consisting of 4 leads. The electrodes have thin needles and attach to the ear at points (preauricular, lobule and superior crus) where cranial nerve peripheral branches are located just beneath the skin. A pen light included with the device is used to visualize the neurovasculature features and aid in proper electrode placement.

Cranial electrotherapy stimulation (CES)

CES also known as cranial electrical stimulation, transcranial electrical stimulation, or electrical stimulation therapy, delivers weak pulses of electrical current to the earlobes, mastoid processes, or scalp with devices such as the Alpha-Stim®. CES is being evaluated for a variety of conditions, including pain, insomnia, depression, anxiety, weight loss, and opioid withdrawal.

Interest in cranial electrotherapy stimulation (CES) began in the early 1900s with the theory that weak pulses of electrical current would lead to a calming effect on the central nervous system. The technique was further developed in the U.S.S.R. and Eastern Europe in the 1950s as a treatment for anxiety and depression, and use of CES later spread to Western Europe and the U.S. as a treatment for a variety of psychological and physiological conditions. Presently, the mechanism of action is thought to be the modulation of activity in brain networks by direct action in the hypothalamus, limbic system, and/or the reticular activating system. One device used in the U.S. is the Alpha-Stim CES, which provides pulsed, low-intensity current via clip electrodes that attach to the earlobes. Other devices place the electrodes on the eyelids, frontal scalp, mastoid processes, or behind the ears. Treatments may be administered once or twice daily for a period of several days to several weeks.

Auricular acupuncture points

Auricular electrostimulation involves the stimulation of acupuncture points on the ear. Devices, including the P-Stim™ and E-pulse, have been developed to provide ambulatory auricular electrical stimulation over a period of several days.

One device, the P-Stim, is a single-use miniature electrical stimulator for auricular acupuncture points that is worn behind the ear with a self-adhesive electrode patch. A selection stylus that measures electrical resistance is used to identify 3 auricular acupuncture points. The P-Stim device connects to 3 inserted acupuncture needles with caps and wires. The device is preprogrammed to be on for 180 minutes, then off for 180 minutes. The maximum battery life of this single-use device is 96 hours.

Auricular electrostimulation, like CES, is being evaluated for conditions such as pain, insomnia, depression, anxiety, weight loss, and opioid withdrawal.

External trigeminal nerve stimulation

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

The trigeminal nerve is the fifth and largest cranial nerve. It is directly connected to the brain and controls facial sensation. The nerve either directly or indirectly enters the regions of the brain associated with ADHD and other disorders.

External trigeminal nerve stimulation (eTNS) is a type of transcutaneous electrical nerve stimulation (TENS) and provides a mild electrical pulse to various branches of the trigeminal nerve and tends to increase the activity in the regions of the brain associated with regulating attention and behavior.

Monarch eTNS is a non-invasive, wearable therapy that eliminates many of the risks associated with drugs, implants, and brain surgery.

It is a mild nerve-stimulating device, comprising a portable pulse generator connected to a single-use electric patch, which is placed on the patient's forehead.

Low-level electric signals are transmitted to the electrode patches, which stimulate trigeminal nerve fibers and send therapeutic signals to the areas of the brain known to be involved with ADHD.

Regulatory Status

In 2019, the IB-Stim device (previously known as Neuro-Stim; Innovative Health Solutions, Inc.) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the de novo 513(f)(2) process (DEN180057). Both the IB-Stim and the similar NSS-2 BRIDGE device (Innovative Health Solutions, Inc.) are derivatives of the Electro Auricular Device (Navigant Consulting, Inc.). The IB-Stim device is indicated for patients 11 to 18 years of age with functional abdominal pain associated with IBS when combined with other IBS therapies. It is intended to be used for 120 hours per week up to 3 consecutive weeks. The First Relief v1 (DyAnsys, Inc.) device and the TEA Device (Transtimulation Research, Inc.) were deemed substantially equivalent to the IB-Stim device. FDA product code: QHH.

A number of devices for cranial electrotherapy stimulation have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. In 1992, the Alpha-Stim® CES device (Electromedical Products International) received marketing clearance for the treatment of anxiety, insomnia, and depression. Devices cleared since 2000 are summarized in Table 1. FDA product code: QJQ.

Table 1: Cranial Electrotherapy Stimulation Devices Cleared by the U.S. Food and Drug Administration

Device Name	Manufacturer	Year Cleared	510(k) No	Indications
Modius Stress	Neurovalens Limited	3/27/2024	K232253	Anxiety

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

Modius Sleep	Neurovalens Limited	10/27/2023	K230826	Insomnia
Cervella™	Innovative Neurological Devices	03/07/2019	K182311	Insomnia, depression, anxiety
Cranial Electrical Nerve Stimulator	Johari Digital Healthcare	05/29/2009	K090052	Insomnia, depression, anxiety
Elexoma Medic™	Redplane AG	05/21/2008	K070412	Insomnia, depression, anxiety
CES Ultra™	Neuro-Fitness	04/05/2007	K062284	Insomnia, depression, anxiety
Net-2000 Microcurrent Stimulator	Auri-Stim Medical	10/13/2006	K060158	Insomnia, depression, anxiety
Transcranial Electrotherapy Stimulator-A, Model TESA-1	Kalaco Scientific	07/21/2003	K024377	Insomnia, depression, anxiety

Several devices for electroacupuncture designed to stimulate auricular acupuncture points have been cleared for marketing through the 510(k) process. Devices cleared since 2000 are summarized in Table 2. FDA product code: BWK, PZR.

Table 2. Auricular Electrostimulation Devices Cleared by the US Food and Drug Administration

Device Name	Manufacturer	Date Cleared	510(k) No.	Indication
Sparrow Ascent	Spark Biomedical, Inc	6/20/2023	K230796	Reduce symptoms of opioid withdrawal
Drug Relief v1	DyAnsys, Inc	6/6/2022	K221231	Reduce symptoms of opioid withdrawal
Needle Stimulator	Bozhou Rongjian Medical Appliance Co., Ltd	3/18/2022	K220153	Practice of acupuncture by qualified practitioners of

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

Device Name	Manufacturer	Date Cleared	510(k) No.	Indication
				acupuncture as determined by the states
Needle Stimulator	Wuxi Jiajian Medical Instrument	8/27/2021	K202861	Practice of acupuncture by qualified practitioners of acupuncture as determined by the states
AXUS ES-5 Electro-Acupuncture Device	Lhasa OMS, INC.	02/03/2021	K200636	Practice of acupuncture by qualified practitioners of acupuncture as determined by the states
Drug Relief V1	DyAnsys Inc	11/05/2021	K211971	Reduce symptoms of opioid withdrawal
Sparrow Therapy System	Spark Biomedical, Inc.	01/02/2021	K201873	Reduce symptoms of opioid withdrawal
Drug Relief	DyAnsys Inc	05/02/2018	K173861	Reduce symptoms of opioid withdrawal
Ansistem-Pp	DyAnsys Inc	03/09/2017	K170391	Practice of acupuncture by qualified practitioners of acupuncture as determined by the states
NSS-2 Bridge	Innovative Health Solutions	2017	N/A ^a	Substance use disorders
Stivax System	Biegler GmbH	05/26/2016	K152571	Practice of acupuncture by qualified practitioners as

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

Device Name	Manufacturer	Date Cleared	510(k) No.	Indication
				determined by the states
ANSiStim®	DyAnsys Inc	05/15/2015	K141168	Practice of acupuncture by qualified practitioners as determined by the states
Pantheon Electrostimulator	Pantheon Research	1107/2014	K133980	Practice of acupuncture by qualified practitioners as determined by the states
Electro Auricular Device	Navigant Consulting, Inc.	10/02/2014	K140530	Practice of acupuncture by qualified practitioners as determined by the states
P-Stim	Biegler GMBH	06/27/2014	K140788	Practice of acupuncture by qualified practitioners as determined by the states
Jiajian Cmn Stimulator	Wuxi Jiajian Medical Instrument Co., Ltd.	08/16/2013	K130768	Practice of acupuncture by qualified practitioners as determined by the states
JiaJian Electro-Acupuncture Stimulators	Wuxi Jiajian Medical Instrument Co., Ltd.	04/11/2013	K122812	Practice of acupuncture by qualified practitioners as determined by the states

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

Device Name	Manufacturer	Date Cleared	510(k) No.	Indication
Multi-Purpose Health Device	UPC Medical Supplies, Inc. DBA United Pacific Co.	08/05/2010	K093322	Unknown - Summary not provided
Electro-Acupuncture: Aculife/Model ADOC-01	Inno-Health Technology, Inc.	04/02/2010	K091933	Practice of acupuncture by qualified practitioners as determined by the states
e-Pulse	Medevice Corporation	12/07/2009	K091875	Practice of acupuncture by qualified practitioners as determined by the states
Model ES-130	Ito Co., Ltd.	11/24/2008	K081943	Practice of acupuncture by qualified practitioners as determined by the states
P-Stim™	Neuroscience Therapy Corp.	03/30/2006	K050123	Practice of acupuncture by qualified practitioners as determined by the states
Aculife	Inno-Health Technology, Inc.	03/28/2006	K051197	Practice of acupuncture by qualified practitioners as determined by the states
AcuStim	S.H.P. Intl. Pty., Ltd.	06/12/2002	K014273	As an electroacupuncture device

^a FDA cleared the NSS-2 Bridge Device for Substance Use Disorders through the de novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no legally marketed predicate device to which the device can

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

claim substantial equivalence"
 N/A: Not applicable

In 2019, the FDA permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD) - the Monarch® external Trigeminal Nerve Stimulation (eTNS) System by NeuroSigma. The FDA reviewed the system through the de novo premarket review pathway. This prescription only TENS device is indicated for patients 7 to 12 years of age who are not currently taking prescription ADHD medication. The Monarch eTNS System is intended to be used in the home under the supervision of a caregiver. The device generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient's forehead, just above the eyebrow.

The Generation 2.0 Monarch eTNS System® and the Smile eTNS System were both deemed substantially equivalent products in 2023. Product code: QGL.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

Percutaneous Electrical Nerve Field Stimulation (PENFS)

For individuals with irritable bowel syndrome (IBS) who receive percutaneous electrical nerve field stimulation (PENFS), the evidence includes a subgroup analysis of a single randomized controlled trial (RCT). Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The RCT (N=115) included a heterogeneous population of adolescent patients age 11 to 18 years with pain-related functional gastrointestinal disorders. Treatment was administered for 3 weeks, and reductions in pain were observed with the active device compared with a sham PENFS device at end of treatment and end of follow-up (maximum of 12 weeks). The subgroup of patients with IBS also had improved pain at the end of treatment with the active device compared with the sham device. However, the trial is limited by its small sample size, heterogeneous population of gastrointestinal disorders, lack of bowel habit measurement, and the short duration of follow-up.

Cranial Electrotherapy Stimulation

For individuals who have acute or chronic pain who receive CES, the evidence includes a number of small sham-controlled randomized trial, and pooled analyses. Relevant outcomes are symptoms, morbid events, functional outcomes, and treatment-related morbidity. Three trials studied headache and CES, and 5 trials studied chronic pain and CES. Pooled analyses found marginal benefits for a headache with CES and no benefits for chronic pain with CES. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have psychiatric, behavioral, or neurologic conditions (e.g., depression and anxiety, Parkinson disease, addiction) who receive CES, the evidence includes a number of

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

small sham-controlled randomized trials. Relevant outcomes are symptoms, morbid events, functional outcomes, and treatment-related morbidity. Three RCTs evaluated CES for depression and anxiety and reported inconsistent outcomes. Comparisons between these trials cannot be made due to the heterogeneity in study populations and treatment protocols. Studies evaluating CES for Parkinson disease and smoking cessation do not support the use of CES for these conditions. The evidence is insufficient to determine the effects of the technology on health outcomes.

Auricular Electrostimulation

For individuals who have acute or chronic pain (e.g., acute pain from surgical procedures, chronic back pain, and chronic pain from osteoarthritis or rheumatoid arthritis) who receive auricular electrostimulation, the evidence includes a limited number of trials. Relevant outcomes are symptoms, morbid events, functional outcomes, and treatment-related morbidity. Studies evaluating the effect of electrostimulation technology on acute pain are inconsistent, and the small amount of evidence on chronic pain has methodologic limitations. For example, a comparison of auricular electrostimulation with manual acupuncture for chronic low back pain did not include a sham-control group, and, in a study of rheumatoid arthritis, auricular electrostimulation was compared with autogenic training and resulted in a small improvement in visual analog scale pain scores of unclear clinical significance. Overall, the few published studies have small sample sizes and methodologic limitations. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have obesity who receive auricular electrostimulation, the evidence includes small RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and treatment-related morbidity. The RCTs reported inconsistent results and used different treatment protocols. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have opioid withdrawal symptoms who receive auricular electrostimulation, the evidence includes 2 case series. Relevant outcomes are symptoms, morbid events, functional outcomes, and treatment-related morbidity. Both case series report positive outcomes for the use of CES to treat opioid withdrawal symptoms. The studies used different treatment protocols and no comparators, limiting conclusions drawn from the results. The evidence is insufficient to determine the effects of the technology on health outcomes.

External trigeminal nerve stimulation

For individuals who have attention deficit hyperactivity disorder (ADHD) who receive TENS, the evidence includes an RCT. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Results of the RCT concluded that TENS is an effective and safe treatment option for pediatric patients with ADHD. However, the study included a small patient sample and was of short duration. Further studies comparing TENS to standard of care therapy for ADHD are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

V. DEFINITIONS
NA

[TOP](#)

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross' medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered:

Procedure Codes							
A4596	E0732	E0733	S8930	64999	0783T		

Covered when medically necessary for the treatment of functional abdominal pain:

Procedure Codes							
0720T							

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

***Medical necessity for functional abdominal pain should consist of one dx from K58 and one dx from R10**

ICD-10-CM Diagnosis Code	Description
K58.0	Irritable bowel syndrome with diarrhea
K58.1	Irritable bowel syndrome with constipation
K58.2	Mixed irritable bowel syndrome
K58.8	Other irritable bowel syndrome
K58.9	Irritable bowel syndrome without diarrhea
R10.10	Upper abdominal pain, unspecified
R10.11	Right upper quadrant pain
R10.12	Left upper quadrant pain
R10.13	Epigastric pain
R10.30	Lower abdominal pain, unspecified
R10.31	Right lower quadrant pain
R10.32	Left lower quadrant pain
R10.33	Periumbilical pain
R10.811	Right upper quadrant abdominal tenderness
R10.812	Left upper quadrant abdominal tenderness
R10.813	Right lower quadrant abdominal tenderness
R10.814	Left lower quadrant abdominal tenderness
R10.815	Periumbilic abdominal tenderness
R10.816	Epigastric abdominal tenderness
R10.817	Generalized abdominal tenderness
R10.819	Abdominal tenderness, unspecified site
R10.821	Right upper quadrant rebound abdominal tenderness
R10.822	Left upper quadrant rebound abdominal tenderness
R10.823	Right lower quadrant rebound abdominal tenderness

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

ICD-10-CM Diagnosis Code	Description
R10.824	Left lower quadrant rebound abdominal tenderness
R10.825	Periumbilic rebound abdominal tenderness
R10.826	Epigastric rebound abdominal tenderness
R10.827	Generalized rebound abdominal tenderness
R10.829	Rebound abdominal tenderness, unspecified site
R10.84	Generalized abdominal pain
R10.9	Unspecified abdominal pain

IX. REFERENCES

[TOP](#)

1. *IBS Facts and Statistics*. International Foundation for Gastrointestinal Disorders. <https://aboutibs.org/what-is-ibs/facts-about-ibs/>. Accessed March 7, 2023.
2. *Definition & Facts for Irritable Bowel Syndrome*. National Institute of Diabetes and Digestive and Kidney Diseases. <https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome/definition-facts>. Updated November 2017. Accessed March 7, 2023.
3. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. *Am J Gastroenterol*. Jan 01 2021; 116(1): 17-44. PMID 33315591
4. Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. *Gastroenterology*. Jul 2022; 163(1): 137-151. PMID 35738725
5. Chang L, Sultan S, Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. *Gastroenterology*. Jul 2022; 163(1): 118-136. PMID 35738724
6. *IB-Stim*. <https://ibstim.com/research/#FDA-Classification>. Accessed March 14, 2023.
7. Kovacic K, Hainsworth K, Sood M, et al. Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial. *Lancet Gastroenterol Hepatol*. Oct 2017; 2(10): 727-737. PMID 28826627
8. Krasaelap A, Sood MR, Li BUK, et al. Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. *Clin Gastroenterol Hepatol*. Aug 2020; 18(9): 1987-1994.e2. PMID 31622740
9. Kovacic K, Kolacz J, Lewis GF et al. Impaired vagal efficiency predicts auricular neurostimulation response in adolescent functional abdominal pain disorders. *Am J Gastroenterol*. 2020; 115(9):1534-1538.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

10. U.S. Food & Drug Administration. FDA News Release: FDA grants marketing authorization of the first device for use in helping to reduce the symptoms of opioid withdrawal. November 15, 2017.
11. Klawansky S, Yeung A, Berkey C, et al. Meta-analysis of randomized controlled trials of cranial electrostimulation. Efficacy in treating selected psychological and physiological conditions. *J Nerv Ment Dis.* Jul 1995; 183(7): 478-84. PMID 7623022
12. Brønfort G, Haas M, Evans RL, Goldsmith CH, Assendelft WJ, Bouter LM. WITHDRAWN: Non-invasive physical treatments for chronic/recurrent headache. *Cochrane Database Syst Rev.* 2014;2014(8):CD001878. Published 2014 Aug 26. doi:10.1002/14651858.CD001878.pub3 O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev.* Apr 11, 2014; (4): CD008208. PMID 24729198
13. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev.* Apr 11 2014; (4): CD008208. PMID 24729198
14. O'Connell NE, Marston L, Spencer S, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev.* Mar 16 2018; 3(3): CD008208. PMID 29547226
15. Ahn H, Galle K, Mathis KB, et al. Feasibility and efficacy of remotely supervised cranial electrical stimulation for pain in older adults with knee osteoarthritis: A randomized controlled pilot study. *J Clin Neurosci.* Jul 2020; 77: 128-133. PMID 32402609
16. Price L, Briley J, Haltiwanger S, et al. A meta-analysis of cranial electrotherapy stimulation in the treatment of depression. *J Psychiatr Res.* Mar 2021; 135: 119-134. PMID 33477056
17. Kavirajan HC, Lueck K, Chuang K. Alternating current cranial electrotherapy stimulation (CES) for depression. *Cochrane Database Syst Rev.* Jul 08, 2014; (7): CD010521. PMID 25000907
18. Ching PY, Hsu TW, Chen GW, et al. Efficacy and Tolerability of Cranial Electrotherapy Stimulation in the Treatment of Anxiety: A Systemic Review and Meta-Analysis. *Front Psychiatry.* 2022; 13: 899040. PMID 35757229
19. Patel S, Boutry C, Patel P, et al. A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial). *Trials.* Apr 04 2022; 23(1): 250. PMID 35379314
20. Kim J, Kim H, Kim DH, et al. Effects of cranial electrotherapy stimulation with novel in-ear electrodes on anxiety and resting-state brain activity: A randomized double-blind placebo-controlled trial. *J Affect Disord.* Dec 01 2021; 295: 856-864. PMID 34706456
21. Barclay TH, Barclay RD. A clinical trial of cranial electrotherapy stimulation for anxiety and comorbid depression. *J Affect Disord.* Aug 2014; 164: 171-7. PMID 24856571
22. Shekelle PG, Cook IA, Miake-Lye IM, et al. Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions, Depression, Anxiety, and Insomnia: A Systematic Review. *Ann Intern Med.* Mar 20, 2018; 168(6): 414-421. PMID 29435567

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

23. Mischoulon D, De Jong MF, Vitolo OV, et al. Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study. *J Psychiatr Res.* Nov 2015; 70: 98-105. PMID 26424428
24. Lyon D, Kelly D, Walter J, et al. Randomized sham controlled trial of cranial microcurrent stimulation for symptoms of depression, anxiety, pain, fatigue, and sleep disturbances in women receiving chemotherapy for early-stage breast cancer. *Springerplus.* 2015; 4: 369. PMID 26435889
25. Shill HA, Obradov S, Katsnelson Y, et al. A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease. *Mov Disord.* Jul 2011; 26(8): 1477-80. PMID 21538515
26. Pickworth WB, Fant RV, Butschky MF, et al. Evaluation of cranial electrostimulation therapy on short-term smoking cessation. *Biol Psychiatry.* Jul 15, 1997; 42(2): 116-21. PMID 9209728
27. Wu WJ, Wang Y, Cai M, et al. A double-blind, randomized, sham-controlled study of cranial electrotherapy stimulation as an add-on treatment for tic disorders in children and adolescents. *Asian J Psychiatr.* Jun 2020; 51: 101992. PMID 32145674
28. Gong BY, Ma HM, Zang XY, et al. Efficacy of Cranial Electrotherapy Stimulation Combined with Biofeedback Therapy in Patients with Functional Constipation. *J Neurogastroenterol Motil.* Jul 3, 0 2016; 22(3): 497-508. PMID 26932836
29. Sator-Katzenschlager SM, Michalek-Sauberer A. P-Stim auricular electroacupuncture stimulation device for pain relief. *Expert Rev Med Devices.* Jan 2007; 4(1): 23-32. PMID 17187468
30. Holzer A, Leitgeb U, Spacek A, et al. Auricular acupuncture for postoperative pain after gynecological surgery: a randomized controlled trail. *Minerva Anesthesiol.* Mar 2011; 77(3): 298-304. PMID 21441884
31. Sator-Katzenschlager SM, Scharbert G, Kozek-Langenecker SA, et al. The short- and long-term benefit in chronic low back pain through adjuvant electrical versus manual auricular acupuncture. *Anesth Analg.* May 2004; 98(5): 1359-64, table of contents. PMID 15105215
32. Sator-Katzenschlager SM, Szeles JC, Scharbert G, et al. Electrical stimulation of auricular acupuncture points is more effective than conventional manual auricular acupuncture in chronic cervical pain: a pilot study. *Anesth Analg.* Nov 2003; 97(5): 1469-73. PMID 14570667
33. Bernateck M, Becker M, Schwake C, et al. Adjuvant auricular electroacupuncture and autogenic training in rheumatoid arthritis: a randomized controlled trial. *Auricular acupuncture and autogenic training in rheumatoid arthritis. Forsch Komplementmed.* Aug 2008; 15(4): 187-93. PMID 18787327
34. Kim SY, Shin IS, Park YJ. Effect of acupuncture and intervention types on weight loss: a systematic review and meta-analysis. *Obes Rev.* Nov 2018; 19(11): 1585-1596. PMID 30180304

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

35. Schukro RP, Heiserer C, Michalek-Sauberer A, et al. The effects of auricular electroacupuncture on obesity in female patients--a prospective randomized placebo-controlled pilot study. *Complement Ther Med.* Feb 2014; 22(1): 21-5. PMID 24559812
36. Yeh ML, Chu NF, Hsu MY, et al. Acupoint Stimulation on Weight Reduction for Obesity: A Randomized Sham-Controlled Study. *West J Nurs Res.* Dec 2015; 37(12): 1517-30. PMID 25183702
37. Yeh TL, Chen HH, Pai TP, et. al. The Effect of Auricular Acupoint Stimulation in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Evidence-Based Complementary and Alternative Medicine.* 2017; vol. 2017, Article ID 3080547, 16 pages, 2017. Accessed May 11, 2022.
38. Kroening RJ, Oleson TD. Rapid narcotic detoxification in chronic pain patients treated with auricular electroacupuncture and naloxone. *Int J Addict.* Sep 1985; 20(9): 1347-60. PMID 2867052
39. Miranda A, Taca A. Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment. *Am J Drug Alcohol Abuse.* 2018; 44(1): 56-63. PMID 28301217
40. Wolraich ML, Hagan JF Jr, Allan C, et al.; Subcommittee on children and adolescents with attention-deficit/hyperactive disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics.* 2019 Oct;144(4): PMID 30768393
41. McGough JJ, Sturm A, Cowen J, et al. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry.* Apr 2019; 58(4): 403-411.e3. PMID 30768393
42. Food and Drug Administration. Axon Therapy Device: K210021. 2021; https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210021.pdf.
43. Blue Cross Blue Shield Association Medical Policy Reference Manual. 1.01.09, Transcutaneous Electrical Nerve Stimulation. January 2024.
44. Blue Cross Blue Shield Association Medical Policy Reference Manual. 2.01.106, Percutaneous Electrical Nerve Field Stimulation for Irritable Bowel Syndrome. June 2023.
45. Blue Cross Blue Shield Association Medical Policy Reference Manual. 8.01.58, Cranial Electrotherapy Stimulation and Auricular Electrostimulation. March 2024.

X. POLICY HISTORY

[TOP](#)

MP 2.092	08/15/2019 Consensus Review. Policy statement unchanged. Tables under Background/Description section updated. References Updated.
	01/01/2020 Administrative Update. Added new code K1002.
	07/01/2020 Consensus Review. No changes. References updated and coding reviewed.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION, CRANIAL ELECTROTHERAPY STIMULATION, AURICULAR ELECTROSTIMULATION, AND EXTERNAL TRIGEMINAL NERVE STIMULATION
POLICY NUMBER	MP 2.092

	03/10/2021 Consensus Review. No changes to policy statement. References updated and coding reviewed. Background/Description section updated.
	05/27/2021 Consensus Review. Added new codes K1016 and K1017, updated Background/Description and References
	09/20/2021 Minor Review. Added Percutaneous Electrical Nerve Field Stimulator to MP as NMN. Added CPT code 64999 and HCPC code E1399 as NMN for treatment of functional abdominal pain.
	05/11/2022 Consensus Review. Updated coding and references.
	06/10/2022 Administrative Update. Added procedure code 0720T effective 7/1/2022.
	09/12/2022 Administrative Update. Added procedure code A4596 effective 10/1/2022.
	11/29/2022 Administrative Update. Added procedure code 0783T
	04/06/2023 Consensus Review. Updated background, rationale, and references.
	11/29/2023 Minor Review. Added MN criteria for the IB-stim device. Updated background, rationale, coding table, and references.
	12/12/2023 Administrative Update. Deleted K1002, K1016, K1017. Added E0732-E0733.
	04/17/2024 Consensus Review. Updated background, rationale, and references. No changes to coding.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.